Status:

COMPLETED

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Lead Sponsor:

BeiGene

Conditions:

High-risk Neuroblastoma

Eligibility:

All Genders

12+ years

Phase:

PHASE1

Brief Summary

This was an open-label, multi-center, single-arm, Phase 1 study. The purpose of this study was for evaluating the safety and pharmacokinetics of dinutuximab beta as maintenance therapy in Chinese part...

Eligibility Criteria

Inclusion

  • Signed informed consent form (ICF) and ability to comply with study requirements
  • Age ≥ 12 months at consent
  • Diagnosis of high-risk neuroblastoma according to the International Neuroblastoma Staging System (INSS) criteria.
  • Participants who have previously received induction chemotherapy and achieved a partial or complete response followed by myeloablative therapy and stem cell transplantation. Stem cell transplantation should be completed within 120 days of dinutuximab beta first administration
  • Exclusion Criteria:
  • Hypersensitivity to ≥ 1 component of dinutuximab beta antibody or against mouse proteins
  • Actively progressive disease (not stabilized) or recurrent disease at the time of inclusion into the study
  • Previous treatment with anti-GD2 antibody before enrolling in this study
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply

Exclusion

    Key Trial Info

    Start Date :

    June 7 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 29 2023

    Estimated Enrollment :

    8 Patients enrolled

    Trial Details

    Trial ID

    NCT05373901

    Start Date

    June 7 2022

    End Date

    June 29 2023

    Last Update

    October 4 2024

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

    Shanghai, Shanghai Municipality, China

    2

    Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

    3

    The Children's Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China